# OnCo record amsokigene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/amsokigene-autoleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "amsokigene-autoleucel" ;
  schema:name "Amsokigene autoleucel"@en ;
  schema:alternateName "OBX-115"@en, "Amsoki-cel"@en, "amsoki-cel"@en, "cytoTIL15"@en ;
  schema:description "Amsokigene autoleucel is an experimental engineered autologous tumour-infiltrating lymphocyte cell therapy from Obsidian Therapeutics, in phase 2 trials for unresectable or metastatic melanoma resistant to checkpoint inhibitors and relapsed or refractory metastatic non-small cell lung cancer."@en ;
  schema:url <https://onco.cc/drugs/amsokigene-autoleucel/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://obsidiantx.com/our-lead-clinical-program/>, <https://obsidiantx.com/our-science/>, <https://obsidiantx.com/our-science/>, <https://obsidiantx.com/our-science/>, <https://clinicaltrials.gov/search?intr=OBX-115> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Engineered autologous tumour-infiltrating lymphocyte (TIL) cell therapy" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/> ;
  onco:companies <https://onco.cc/companies/obsidian-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct06060613/>, <https://onco.cc/trials/nct05470283/> .